{'fraction_non_alphanumeric': 0.042801556420233464, 'fraction_numerical': 0.01556420233463035, 'mean_word_length': 4.676470588235294, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Treatment of Type 2 Diabetes mellitus (T2DM): Can GLP-1 Receptor Agonists fill in the gaps?

GLP-1 receptor (GLP-1R), one of the class-B G-protein-coupled receptors (GPCR), is a budding molecular target to design drugs for treating type 2 diabetes. In this review, authors have summarized the physiological actions of Glucagon-like peptide-1 receptor (GLP-1R) and currently available drugs based on GLP-1 Receptor Agonists (GLP-1 RAs). The exemplary studies in this area have been examined in detail. GLP-1 RAs offer a chance of holistic management of this disease because they help in controlling the main condition and manage the related side effects too. Careful adjustment and monitoring of the dosage of GLP-1 receptor agonists is required to manage adverse effects.